Covid-19 is a novel infectious disease whose spectrum of presentation ranges from absence of symptoms to widespread interstitial pneumonia associated with severe acute respiratory syndrome (SARS), leading to significant mortality. Given the systemic pattern of Covid-19, there are many factors that can influence patient's functional capacity after acute infection and the identification of such factors can contribute to the development of specific rehabilitation strategies. Pulmonary impairment is the primary cause of hospitalization due to Covid-19, and can progress to SARS as well as increase length of hospitalization. Moreover, cardiac involvement is observed in approximately 30% of hospitalized patients, with an increased risk of acute myocarditis, myocardial injury, and heart failure, which may compromise functional capacity in the long-term. Thromboembolic complications have also been reported in some patients with Covid-19 and are associated with a poor prognosis. Musculoskeletal complications may result from long periods of hospitalization and immobility, and can include fatigue, muscle weakness and polyneuropathy. Studies that address the functional capacity of patients after Covid-19 infection are still scarce. However, based on knowledge from the multiple systemic complications associated with Covid-19, it is reasonable to suggest that most patients, especially those who underwent prolonged hospitalization, will need a multiprofessional rehabilitation program. Further studies are needed to evaluate the functional impact and the rehabilitation strategies for patients affected by Covid-19.

Diversos estudos têm demonstrado um efeito benéfico do exercício de força sobre a redução da pressão arterial (PA) pós-exercício, mas ainda são escassas as pesquisas envolvendo pessoas hipertensas. Dessa forma, o presente estudo tem como objetivo comparar as respostas de PA em sujeitos hipertensos medicados após duas sessões de exercício de força com diferentes volumes de treinamento. Para tal, foram estudados 20 indivíduos de ambos os gêneros (61 ± 12 anos) com hipertensão controlada por fármacos e participantes de um programa de exercícios, porém sem experiência no treinamento de força. O estudo foi realizado em três dias não consecutivos. Primeiramente, foi determinada a carga de 10 repetições máximas em cada exercício da seqüência (supino reto, leg-press horizontal, remada em pé e rosca tríceps). Nos demais dias, os mesmos exercícios foram realizados com uma (SER1) ou três (SER3) séries. A aferição da PA foi executada pelo método auscultatório no momento pré-exercício, imediatamente após o término de cada sessão e durante 60 minutos após o término dos exercícios. A ANOVA de medidas repetidas identificou que em ambas as sessões os valores da PA sistólica (PAS) e diastólica (PAD), medidos imediatamente após o término dos exercícios, foram mais elevados (p < 0,05) que os do pré-exercício. O acompanhamento em 60 minutos exibiu, após SER1, uma redução dos valores de PAS apenas no 40º minuto, enquanto não foram encontradas reduções para a PAD. Já após SER3, observou-se uma queda dos níveis de PAS que perdurou por todo o período de monitorização. Para PAD, foram encontradas reduções apenas no 30º e 50º minuto pós-exercício. Conclui-se que uma sessão de treinamento de força pode promover reduções nos níveis de PAS em indivíduos hipertensos medicados e parece ser necessário um maior volume de treinamento para que tal efeito ocorra.

Background Chagas disease (CD) remains an important endemic disease in Latin America. However, CD became globalized in recent decades. The majority of the chronically infected individuals did not receive etiologic treatment for several reasons, among them the most conspicuous is the lack of access to diagnosis. The impact of trypanocidal treatment on CD chronic phase, without cardiac involvement (indeterminate form ICF), is yet to be determined. We aimed to evaluate the effect of trypanocidal treatment with benznidazole (BZN) on the rate of progression to Chagas heart disease in patients with ICF. Methods This is a retrospective cohort observational study including patients with ICF treated with BZN and compared to a group of non-treated patients matched for age, sex, region of origin, and the year of cohort entry. We reviewed the medical charts of all patients followed from May 1987 to June 2020 at the outpatient center of the Evandro Chagas National Institute of Infectious Diseases (INI) of the Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil. Patients’ follow-up included at least one annual medical visit and one annual electrocardiogram (ECG). Echocardiographic exams were performed at baseline and during the follow-up. Disease progression from ICF to cardiac form was defined by changes in baseline ECG. Cumulative incidence and the incidence rate were described in the incidence analysis. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals for the association between BZN and CD progression, cardiovascular events or death. Findings One hundred and fourteen treated patients met the study inclusion criteria. A comparison group of 114 non-treated patients matched for age, sex, region of origin, and the year of cohort entry was also included, totalizing 228 patients. Most patients included in the study were male (70.2%), and their mean age was 31.3 (+7.4) years. Over a median follow-up of 15.1 years (ranging from 1.0 to 32.4), the cumulative CD progression incidence in treated patients was 7.9% vs. 21.1% in the non-treated group ( p = 0.04) and the CD progression rate was 0.49 per 1.000 patients/year in treated patients vs. 1.10 per 1.000 patients/year for non-treated patients ( p = 0.02). BZN treatment was associated with a decreased risk of CD progression in both unadjusted (HR 0.46; 95%CI 0.21 to 0.98) and adjusted (HR 0.43; 95%CI 0.19 to 0.96) models and with a decreased risk of occurrence of the composite of cardiovascular events only in the adjusted (HR 0.15; 95%CI 0.03 to 0.80) model. No association was observed between BZN treatment and mortality. Interpretation In a long-term follow-up, BZN treatment was associated with a decreased incidence of CD progression from ICF to the cardiac form and also with a decreased risk of cardiovascular events. Therefore, our results indicate that BZN treatment for C...

Benznidazole treatment was safe and a large proportion of patients were able to complete a full course of benznidazole treatment under close treatment surveillance. Female sex, skin disorders and mild and moderate ADRs were independently associated with the permanent suspension of benznidazole treatment. In particular, women with moderate skin ADRs had the highest risk of benznidazole treatment interruption.